Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Theratechnologies ( (TSE:TH) ).
Theratechnologies Inc. has filed a Prior Approval Supplement with the U.S. FDA regarding changes to the manufacturing environment of their product, EGRIFTA SV®. The company anticipates an FDA review within four months and is actively engaging with FDA divisions to prevent a possible shortage of EGRIFTA SV® for patients, as current inventory is expected to last until mid-January 2025.
More about Theratechnologies
Theratechnologies Inc. is a biopharmaceutical company that specializes in developing and commercializing innovative therapies aimed at addressing unmet medical needs. The company is publicly traded on the TSX and NASDAQ, focusing on therapies such as EGRIFTA SV® which is distributed solely in the United States.
YTD Price Performance: 9.26%
Average Trading Volume: 59,530
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $81.56M
Learn more about TH stock on TipRanks’ Stock Analysis page.